Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer: A phase II study of Okayama Lung Cancer Study Group

British Journal of Cancer

Volumn 85, Issue 1, 2001, Pages 9-13

  Ueoka, H ^a   Tanimoto, M ^a   Kiura, K ^a   Tabata, M ^a   Takigawa, N ^a   Segawa, Y ^b   Takata, I ^b   Eguchi, K ^b   Okimoto, N ^c   Harita, S ^d   Kamei, H ^e   Shibayama, T ^f   Watanabe, Y ^g   Hiraki, S ^g   Harada, M ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d CHUGOKU CENTRAL HOSPITAL   (Japan)

^e Sumitomo Besshi Hospital   (Japan)

^f Okayama Health Foundation Hospital   (Japan)

^g Japanese Red Cross Okayama Hospital   (Japan)

Author keywords

Cisplatin; Fractionated administration; Irinotecan; Non small cell lung cancer; Phase II study

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; FRACTIONATION; HUMAN; HUMAN TISSUE; JAPAN; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING;

EID: 17844372728     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1861     Document Type: Article

References (23)

1. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
2. Down-regulation of topoisomerase I induced by cisplatin
3. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
4. New chemotherapeutic agents prolong survival and improvequality of life in non-small cell lung cancer: A review of the literature and future directions
5. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
6. A phase II study of CPT- II, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer
7. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough?
8. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
9. Evolution of cisplatin-based chemotherapy in non-small cell lung cancer-A historical perspective and the Eastern Cooperative Oncology Group experience
10. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer
11. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts
12. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors
13. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
14. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer
15. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer
16. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group
17. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study
18. Phase I study of weekly intravenous infusion of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer
19. Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC)
20. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials
21. Toxicity and response criteria of the Eastern Cooperative Oncology Group
22. Polychemotherapy in advanced non small cell lung cancer: A meta-analysis
23. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: A phase I study